High rates of primary Mycobacterium avium complex and Pneumocystis jiroveci prophylaxis in the United States

Medical Care

Volumn 43, Issue 9 SUPPL., 2005, Pages

  Gebo, Kelly A ^a   Fleishman, John A ^b   Reilly, Erin D ^a   Moore, Richard D ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b AGENCY FOR HEALTHCARE RESEARCH AND QUALITY   (United States)

Author keywords

Disparities; Gender; HIV; Mycobacterium avium complex; Opportunistic illness prophylaxis; Pneumocystis jiroveci

Indexed keywords

EID: 24944587548     PISSN: 00257079     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.mlr.0000175631.34438.1e     Document Type: Article

References (29)

1. 2001 USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus. HIV Clin Trials. 2001;2:493-554.
2. Centers for Disease Control and Prevention. HIV/AIDS Surveillance Supplemental Report. 2001;7.
3. Hargraves JL, Cunningham PJ, Hughes RG. Racial and ethnic differences in access to medical care in managed care plans. Health Serv Res. 2001;36:853-868.
4. Kressin NR, Petersen LA. Racial differences in the use of invasive cardiovascular procedures: review of the literature and prescription for future research. Ann Intern Med. 2001;135:352-366.
5. Schneider EC, Cleary PD, Zaslavsky AM, et al. Racial disparity in influenza vaccination: does managed care narrow the gap between African Americans and whites? JAMA. 2001;286:1455-1460.
6. Garg PP, Diener-West M, Powe NR. Reducing racial disparities in transplant activation: whom should we target? Am J Kidney Dis. 2001;37:921-931.
7. Asch SM, Gifford AL, Bozzette SA, et al. Underuse of primary Mycobacterium avium complex and Pneumocystis carinii prophylaxis in the United States. J Acquir Immun Defic Syndr. 2001;28:340-344.
8. McLaughlin TJ, Soumerai SB, Weinrib D, et al. The association between primary source of ambulatory care and access to outcomes of treatment among AIDS patients. Int J Qual Health Care. 1999;11:293.
9. Moore RD, Stanton D, Gopalan R, et al. Racial differences in the use of drug therapy for HIV disease in an urban community. N Engl J Med. 1994;330:763-768.
10. Solomon L, Stein M, Flynn C, et al. Health services use by urban women with or at risk for HIV-1 infection: the HIV Epidemiology Research Study (HERS). J Acquir Immun Defic Syndr Hum Retrovirol. 1998;17:253-261.
11. Kass N, Flynn C, Jacobson L, et al. Effect of race on insurance coverage and health service use for HIV-infected gay men. J Acquir Immun Defic Syndr Hum Retrovirol. 1999;20:85-92.
12. Wolfe M, Hanson D, Teshale E, et al., Adult and Adolescent Spectrum of HIV Disease Investigators CDC, Atlanta, GA. Reasons for lack of appropriate receipt of primary PCP prophylaxis in a large cohort of HIV-infected persons in care in the United States, 1993-2002. In: Abstracts of the llth Conference on Retroviruses and Opportunistic Illnesses; San Francisco, CA; February 8-11, 2004: Poster 767.
13. Shapiro MF, Morton SC, McCaffrey DF, et al. Variations in the care of HIV-infected adults in the United States: results from the HIV Cost and Services Utilization Study. JAMA. 1999;281:2305-2315.
14. Weissman JS, Makadon HJ, Seage GR III, et al. Changes in insurance status and access to care for persons with AIDS in the Boston Health Study. Am J Public Health. 1994;84:1997.
15. Graham NM, Jacobson LP, Kuo V, et al. Access to therapy in the Multicenter AIDS Cohort Study, 1989-1992. J Clin Epidemiol. 1994;47:1003-1012.
16. Smith SR, Kirking DM. Access and use of medications in HIV disease. Health Serv Res. 1999;34:123-144.
17. Jeffe DB, Meredith KL, Mundy LM, et al. Factors associated with HIV-infected patients' recognition and use of HIV medications. J Acquir Immun Defic Syndr Hum Retrovirol. 1998;19:350-360.
18. Sackoff J, McFarland J, Su S, et al. Prophylaxis for opportunistic infections among HIV-infected patients receiving medical care. J Acquir Immun Defic Syndr Hum Retrovirol. 1998;19:387-392.
19. Palacio H, Kahn JG, Richards TA, et al. Effect of race and/or ethnicity in use of antiretrovirals and prophylaxis for opportunistic infection: a review of the literature. Public Health Rep. 2002;117:233.
20. Carpenter CCJ, Cooper DA, Fischl MA, et al. Antiretroviral therapy in adults: updated recommendations of the International AIDS Society - USA Panel. JAMA. 2000;283:381.
21. Yeni PG, Hammer SM, Carpenter CC, et al. Antiretroviral treatment for adult HIV infection in 2002: updated recommendations of the International AIDS Society - USA Panel. JAMA. 2002;288:222-235.
22. McNaghten AD, Hanson DL, Dworkin MS, et al. Differences in prescription of antiretroviral therapy in a large cohort of HIV-infected patients. J Acquir Immun Defic Syndr. 2003;32:499-505.
23. Andersen R, Bozzette S, Shapiro M, et al. Access of vulnerable groups to antiretroviral therapy among persons in care for HIV disease in the United States. HCSUS Consortium. HIV Cost and Services Utilization Study. Health Serv Res. 2000;35:389-416.
24. Gebo K, Fleishman J, Conviser R, et al. Racial and gender disparities in receipt of HAART persist in a multi-state sample of HIV patients in 2001. J Acquir Immun Defic Syndr. 2005;38:96-103.
25. Cunningham WE, Markson LE, Andersen RM, et al. Prevalence and predictors of highly active antiretroviral therapy use in patients with HIV infection in the united states. HCSUS Consortium. HIV Cost and Services Utilization. J Acquir Immun Defic Syndr. 2000;25:115-123.
26. Lucas GM, Gebo KA, Chaisson RE, et al. Longitudinal assessment of the effects of drug and alcohol abuse on HIV-1 treatment outcomes in an urban clinic. AIDS. 2002;16:767-774.
27. Lucas GM, Cheever LW, Chaisson RE, et al. Detrimental effects of continued illicit drug use on the treatment of HIV-1 infection. J Acquir Immun Defic Syndr. 2001;27:251-259.
28. Crystal S, Sambamoorthi U, Moynihan PJ, et al. Initiation and continuation of newer antiretroviral treatments among medicaid recipients with AIDS. J Gen Intern Med. 2001;16:850-859.
29. Huskamp HA, Deverka PA, Epstein AM, et al. The effect of incentive-based formularies on prescription-drug utilization and spending. N Engl J Med. 2003;349:2224-2232.